KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Japanese participant data from three gantenerumab trials in early Alzheimer's disease.

Takashi Asada, Angeliki Thanasopoulou, Paul Delmar, Jakub Wojtowicz, Janice Smith, Yasumasa Yoshiyama, Katsunori Yokoi, Chigusa Watanabe, Mitsuhiro Isozaki, Ryoto Ozaki, Takaaki Ishida, Hironori Tatsuda, Akira Tamaoka

Alzheimers Dement 21(4) e70192

PMID40302041
PMCIDPMC12040720
DOI10.1002/alz.70192
发表日期2025-04-30
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

INTRODUCTION: Gantenerumab was investigated in Japanese participants with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD in two global phase 3 trials (GRADUATE I/II), and a phase 2 trial in Japan (JP40959). METHODS: Of 1965 participants randomized in GRADUATE I/II (global-GRADUATE), 132 participants were enrolled from Japan (Japanese-GRADUATE) and 67 Japanese participants were randomized 2:1:1 to high-, low-dose gantenerumab, and placebo in JP40959. RESULTS: Slowing of cognitive and functional decline, and amyloid reduction in gantenerumab group compared to placebo group were greater in Japanese-GRADUATE than in the global-GRADUATE and JP40959. Plasma gantenerumab concentrations in the Japanese-GRADUATE were slightly higher than in the global-GRADUATE and comparable to JP40959. Gantenerumab was well tolerated in the Japanese-GRADUATE and JP40959, matching the safety profile of the global-GRADUATE. DISCUSSION: Differences in results across the populations studied could be related to imbalances in baseline body weight, amyloid load, and disease severity. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov ID: NCT03444870, NCT03443973; Japan Registry for Clinical Trials ID: jRCT2080224569. HIGHLIGHTS: Gantenerumab was evaluated in Japanese participants with Alzheimer's disease (AD) in two global phase 3 trials and a phase 2 trial in Japan. Relative reduction in Clinical Dementia Rating Sum of Boxes (CDR-SB) deterioration favored gantenerumab in Japanese-GRADUATE (42%) more than in global-GRADUATE (9%) and JP40959 (-24%). Amyloid reduction in Japanese-GRADUATE was greater than in global-GRADUATE and JP40959. Overall, 72.7% and 27.5% of Japanese- and global-GRADUATE, respectively, achieved an amyloid-negative status. Cognitive and functional decline, and amyloid reduction could be related to baseline body weight and disease severity.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。